A Phase 2 Study of Sorafenib in Combination with Cetuximab in EGFR-expressing, KRAS-mutated Metastatic Colorectal Cancer

BACKGROUND: Mutations in the KRAS gene predict for resistance to anti-EGFR therapies, including cetuximab. Upregulation of VEGF-A has been implicated in resistance to anti-EGFR treatment. Abrogation of the VEGF and RAS/RAF/MEK/ERK pathways has the potential to restore cetuximab sensitivity. PATIENTS...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Colorectal Cancer
Main Authors: Do, Khanh, Cao, Liang, Kang, Zhigang, Turkbey, Baris, Lindenberg, Maria L., Larkins, Erin, Holkova, Beata, Steinberg, Seth M., Raffeld, Mark, Peer, Cody J., Figg, William D., Eugeni, Michelle, Jacobs, Paula, Choyke, Peter, Wright, John J., Doroshow, James H., Kummar, Shivaani
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6657351/
https://ncbi.nlm.nih.gov/pubmed/25861837
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clcc.2015.02.007
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados